150 related articles for article (PubMed ID: 11953887)
1. Cirrhotic livers reveal genetic changes in the MDM2-P14ARF system of cell cycle regulators.
Schlott T; Scharf JG; Gorzel C; Middel P; Spring H
Br J Cancer; 2002 Apr; 86(8):1290-6. PubMed ID: 11953887
[TBL] [Abstract][Full Text] [Related]
2. Alteration of the MDM2-p73-P14ARF pathway related to tumour progression during urinary bladder carcinogenesis.
Schlott T; Quentin T; Korabiowska M; Budd B; Kunze E
Int J Mol Med; 2004 Nov; 14(5):825-36. PubMed ID: 15492852
[TBL] [Abstract][Full Text] [Related]
3. Genetic alterations of the p14ARF -hdm2-p53 regulatory pathway in breast carcinoma.
Ho GH; Calvano JE; Bisogna M; Abouezzi Z; Borgen PI; Cordón-Cardó C; van Zee KJ
Breast Cancer Res Treat; 2001 Feb; 65(3):225-32. PubMed ID: 11336244
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in liver cirrhosis and hepatocellular carcinoma.
Jablkowski M; Bocian A; Bialkowska J; Bartkowiak J
J Exp Clin Cancer Res; 2005 Mar; 24(1):117-25. PubMed ID: 15943041
[TBL] [Abstract][Full Text] [Related]
5. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer.
Wang YC; Lin RK; Tan YH; Chen JT; Chen CY; Wang YC
J Clin Oncol; 2005 Jan; 23(1):154-64. PubMed ID: 15625370
[TBL] [Abstract][Full Text] [Related]
6. p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53.
Lindström MS; Klangby U; Wiman KG
Oncogene; 2001 Apr; 20(17):2171-7. PubMed ID: 11360201
[TBL] [Abstract][Full Text] [Related]
7. Dysfunction of p53 pathway in human colorectal cancer: analysis of p53 gene mutation and the expression of the p53-associated factors p14ARF, p33ING1, p21WAF1 and MDM2.
Tachibana M; Kawamata H; Fujimori T; Omotehara F; Horiuchi H; Ohkura Y; Igarashi S; Kotake K; Kubota K
Int J Oncol; 2004 Oct; 25(4):913-20. PubMed ID: 15375540
[TBL] [Abstract][Full Text] [Related]
8. Analysis of central regulatory pathways in p53-deficient primary cultures of malignant fibrous histiocytoma exposed to ifosfamide.
Schlott T; Taubert H; Fayyazi A; Schweyer S; Bartel F; Korabiowska M; Brinck U
Anticancer Res; 2004; 24(6):3819-29. PubMed ID: 15736417
[TBL] [Abstract][Full Text] [Related]
9. P14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2.
Xirodimas DP; Chisholm J; Desterro JM; Lane DP; Hay RT
FEBS Lett; 2002 Sep; 528(1-3):207-11. PubMed ID: 12297306
[TBL] [Abstract][Full Text] [Related]
10. Expression of the p14ARF tumor suppressor predicts survival in acute myeloid leukemia.
Müller-Tidow C; Metzelder SK; Buerger H; Packeisen J; Ganser A; Heil G; Kügler K; Adigüzel G; Schwäble J; Steffen B; Ludwig WD; Heinecke A; Büchner T; Berdel WE; Serve H
Leukemia; 2004 Apr; 18(4):720-6. PubMed ID: 14973498
[TBL] [Abstract][Full Text] [Related]
11. MDM2 mRNA expression in the p53 pathway may predict the potential of invasion and liver metastasis in colorectal cancer.
Kondo I; Iida S; Takagi Y; Sugihara K
Dis Colon Rectum; 2008 Sep; 51(9):1395-402. PubMed ID: 18607552
[TBL] [Abstract][Full Text] [Related]
12. Multiple interacting domains contribute to p14ARF mediated inhibition of MDM2.
Clark PA; Llanos S; Peters G
Oncogene; 2002 Jul; 21(29):4498-507. PubMed ID: 12085228
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma.
Tsuchiya T; Sekine K; Hinohara S; Namiki T; Nobori T; Kaneko Y
Cancer Genet Cytogenet; 2000 Jul; 120(2):91-8. PubMed ID: 10942797
[TBL] [Abstract][Full Text] [Related]
14. p53 activation in chronic radiation-treated breast cancer cells: regulation of MDM2/p14ARF.
Xia L; Paik A; Li JJ
Cancer Res; 2004 Jan; 64(1):221-8. PubMed ID: 14729628
[TBL] [Abstract][Full Text] [Related]
15. p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2.
Esteller M; Cordon-Cardo C; Corn PG; Meltzer SJ; Pohar KS; Watkins DN; Capella G; Peinado MA; Matias-Guiu X; Prat J; Baylin SB; Herman JG
Cancer Res; 2001 Apr; 61(7):2816-21. PubMed ID: 11306450
[TBL] [Abstract][Full Text] [Related]
16. Deregulation of the p14ARF/Mdm2/p53 pathway and G1/S transition in two glioblastoma sets.
Ghimenti C; Fiano V; Chiadò-Piat L; Chiò A; Cavalla P; Schiffer D
J Neurooncol; 2003 Jan; 61(2):95-102. PubMed ID: 12622447
[TBL] [Abstract][Full Text] [Related]
17. RT-PCR amplification of RNA extracted from formalin-fixed, paraffin-embedded oral cancer sections: analysis of p53 pathway.
Tachibana M; Shinagawa Y; Kawamata H; Omotehara F; Horiuchi H; Ohkura Y; Kubota K; Imai Y; Fujibayashi T; Fujimori T
Anticancer Res; 2003; 23(3C):2891-6. PubMed ID: 12926130
[TBL] [Abstract][Full Text] [Related]
18. Detection of MDM2 alterations in cultured human hepatocytes treated with 17beta-estradiol or 17alpha-ethinylestradiol.
Schlott T; Thasler W; Gorzel C; Pahernik S; Brinck U; Eiffert H; Droese M
Anticancer Res; 2002; 22(3):1545-51. PubMed ID: 12168835
[TBL] [Abstract][Full Text] [Related]
19. Distinct MDM2 and P14ARF expression and centrosome amplification in well-differentiated liposarcomas.
Perucca-Lostanlen D; Rostagno P; Grosgeorge J; Marcié S; Gaudray P; Turc-Carel C
Genes Chromosomes Cancer; 2004 Feb; 39(2):99-109. PubMed ID: 14695989
[TBL] [Abstract][Full Text] [Related]
20. p16/p14(ARF) cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced stage disease.
Omura-Minamisawa M; Diccianni MB; Chang RC; Batova A; Bridgeman LJ; Schiff J; Cohn SL; London WB; Yu AL
Clin Cancer Res; 2001 Nov; 7(11):3481-90. PubMed ID: 11705866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
